Skip to main content

Table 1 Clinical characteristics of the study population

From: Tryptophan catabolism and immune activation in primary and chronic HIV infection

 

Primary HIV infection N = 14

Early presenters

N = 24

Late presenters

N = 19

Healthy controls

N = 16

P

Gender, males/females, (% males)

13/1 (92.9)

22/2 (91.7)

18/1 (94.7)

15/1 (93.8)

.948

Age, years, mean (SD)

46 (8.9)

45 (8.2)

47 (10.1)

43 (9.4)

.529

CD8+ at baseline, cells/μL, mean (SD)

1238.6 (659.8)

1123.5 (547.5)

820.1 (556.0)

915.7 (409.7)

.116

CD4+ at baseline, cells/μL, mean (SD)

577.8 (228.5) a,d

527.9 (111.2)c,f

72.7 (62.7)a,c,e

1144.0 (329.0)d,e,f

< .001

CD4/CD8 at baseline, mean (SD)

0.6 (0.4)a,d

0.6 (0.2)c,f

0.1 (0.1)a,c,e

1.4 (0.5)d,e,f

< .001

Co-infection with chronic HBV/HCV, N

0/1

1/0

0/2

0/0

NA

HIV RNA at baseline, mean (SD)

2,413,322 (4,119,479)a,b

97,328 (253,967)b,c

486,483 (524,072)a,c

NA

< .001

AIDS defining events, N

0

0

1

NA

NA

KTratio at baseline, mean (SD)

46.8 (20.3)a,b,d

34.8 (10.6)b,c,f

74.5 (48.1)a,c,e

20.9 (3.7)d,e,f

< .001

CD8 + CD38 + HLA-DR+, % cells, mean (SD)

44.7 (20.3) a,b,d

22.0 (13.4)b,c,f

25.5 (21.3)a,c,e

1.3 (0.8)d,e,f

< .001

CD4 + CD38 + HLA-DR+, % cells, mean (SD)

5.5 (4.1)a,d

3.5 (3.0)c,f

15.5 (15.4)a,c,e

0.8 (0.6)d,e,f

< .001

  1. P*: comparing the four groups by using ANOVA if parametric variables or Kruksal-Wallis test if non parametric variables. If significant (<0.05) then t-test if parametric variables or Mann-Whitney if non parametric variables were used to compare two groups. Only significant differences are marked:
  2. aprimary HIV infection vs late presenters
  3. bprimary HIV infection vs early presenters
  4. clate presenters vs early presenters
  5. dhealthy controls vs primary HIV infection
  6. ehealthy controls vs late presenters
  7. fhealthy controls vs early presenters